Carna Biosciences, Inc. provided earnings forecast for the Fiscal Year Ending December 31, 2019. For the year, the company expects Net sales to be JPY 3,206 million compared to previous guidance of JPY 3,038 million. Operating income to be JPY 968 million compared to previous guidance of JPY 313 million. Ordinary income to be JPY 951 million compared to previous guidance of JPY 279 million. Net profit per share to be JPY 72.72 per share compared to previous guidance of JPY 20.12 per share. Carna has upwardly revised its consolidated sales forecast for the fiscal year ending December 31 (FY2019) by 5.5% to JPY 3,206 million from JPY 3,038 million primarily due to the strong sales in North America and China at the Drug Discovery Support business. By business segment, sales forecast for the Drug Discovery Support business was revised to JPY 1,078 million from JPY 938 million as sales of kinase proteins, assay kits, and profiling services were stronger than expected. Sales forecast for the Drug Discovery and Development business was revised to JPY 2,128 million from JPY 2,100 million due to the difference in the expected foreign exchange rate and the actual rate. Consolidated operating profit was upwardly revised by 209.4% to JPY 968 million from JPY 313 million. At the Drug Discovery Support business, operating profit was revised to JPY 403 million from JPY 247 million due to stronger than expected sales. At the Drug Discovery and Development business, operating profit was revised to JPY 564 million from JPY 65 million due to the changes in R&D expense. Consolidate R&D expense is expected to be JPY 1,296 million from the previous forecast of JPY 1,808 million. As a result, forecast for recurring profit was upwardly revised by 240.9% to JPY 951 million and forecast for profit attributable to owners of parent was upwardly revised by 268.9% to JPY 791 million.